Global Osteoarthritis Therapeutic Market

Osteoarthritis Therapeutic Comprehensive Study by Drug (Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics, Corticosteroids), Route of Administration (Parenteral, Topical, Oral), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Anatomy (Knee, Hip, Hand, Small Joints (Foot & Ankle and Wrist )), Purchase Mode (Prescription Drug, Over-the-counter Drug) Players and Region - Global Market Outlook to 2026

Osteoarthritis Therapeutic Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Osteoarthritis Therapeutic?
Osteoarthritis is type of arthritis that occurs when flexible tissue at the ends of bones wears down. Osteoarthritis Therapeutic and Growth in this industry is driven by the rapid growth in the geriatric and obese population and the associated increase in the prevalence of osteoarthritis disease. On the other hand, the availability of alternative non-drug pain management therapies is a major market challenge.

The market study is broken down and major geographies with country level break-up.

The Osteoarthritis Therapeutic market is highly fragmented in nature with a large number of international as well as regional players operating in the market. Analysts at AMA Research estimates that Players from United States will contribute to the maximum growth of Global Osteoarthritis Therapeutic market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Sanofi (France), Horizon Therapeutics (Ireland), Johnson & Johnson (United States), GlaxoSmithKline Plc (United Kingdom), Bayer AG (Germany), Abbott (United States), Pfizer (United States), Eli Lilly (United States), Anika Therapeutics (United States) and Novartis (Switzerland) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Bioventus (United States), Zimmer Biomet Holdings, Inc.(United States), Flexion Therapeutics (United States) and Fidia Farmaceutici s.p.a. (Italy).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Osteoarthritis Therapeutic market by Type, Application and Region.

On the basis of geography, the market of Osteoarthritis Therapeutic has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drug , the sub-segment i.e. Viscosupplementation Agents will boost the Osteoarthritis Therapeutic market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Route of Administration, the sub-segment i.e. Parenteral will boost the Osteoarthritis Therapeutic market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Osteoarthritis Therapeutic market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Anatomy, the sub-segment i.e. Knee will boost the Osteoarthritis Therapeutic market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Purchase Mode, the sub-segment i.e. Prescription Drug will boost the Osteoarthritis Therapeutic market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.




Market Trend
  • Increase in the Prevalence of Osteoarthritis

Market Drivers
  • Rapid Growth in the Geriatric and Obese Populations
  • Increasing Incidence of Sports Injuries

Opportunities
  • Emerging Markets
  • Strategic Collaborations Focused on New Product Development

Restraints
  • Risk of Adverse Cardiovascular Events Associated With the Use of Nsaids in Osteoarthritis Treatment

Challenges
  • Availability of Alternative Non-Drug Pain Management Therapies


Key Target Audience
Hospitals, Medical Centers, Research Firm, Government Organization, Medical Laboratories and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Drug
  • Viscosupplementation Agents
  • Nonsteroidal Anti-inflammatory Drugs
  • Analgesics
  • Corticosteroids

By Route of Administration
  • Parenteral
  • Topical
  • Oral

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Anatomy
  • Knee
  • Hip
  • Hand
  • Small Joints (Foot & Ankle and Wrist )

By Purchase Mode
  • Prescription Drug
  • Over-the-counter Drug

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rapid Growth in the Geriatric and Obese Populations
      • 3.2.2. Increasing Incidence of Sports Injuries
    • 3.3. Market Challenges
      • 3.3.1. Availability of Alternative Non-Drug Pain Management Therapies
    • 3.4. Market Trends
      • 3.4.1. Increase in the Prevalence of Osteoarthritis
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Osteoarthritis Therapeutic, by Drug , Route of Administration, Distribution Channel, Anatomy, Purchase Mode and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Osteoarthritis Therapeutic (Value)
      • 5.2.1. Global Osteoarthritis Therapeutic by: Route of Administration (Value)
        • 5.2.1.1. Parenteral
        • 5.2.1.2. Topical
        • 5.2.1.3. Oral
      • 5.2.2. Global Osteoarthritis Therapeutic by: Distribution Channel (Value)
        • 5.2.2.1. Hospital Pharmacies
        • 5.2.2.2. Retail Pharmacies
        • 5.2.2.3. Online Pharmacies
      • 5.2.3. Global Osteoarthritis Therapeutic by: Anatomy (Value)
        • 5.2.3.1. Knee
        • 5.2.3.2. Hip
        • 5.2.3.3. Hand
        • 5.2.3.4. Small Joints (Foot & Ankle and Wrist )
      • 5.2.4. Global Osteoarthritis Therapeutic by: Purchase Mode (Value)
        • 5.2.4.1. Prescription Drug
        • 5.2.4.2. Over-the-counter Drug
      • 5.2.5. Global Osteoarthritis Therapeutic Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Osteoarthritis Therapeutic: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sanofi (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Horizon Therapeutics (Ireland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Johnson & Johnson (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GlaxoSmithKline Plc (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bayer AG (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Abbott (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Eli Lilly (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Anika Therapeutics (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Novartis (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Osteoarthritis Therapeutic Sale, by Drug , Route of Administration, Distribution Channel, Anatomy, Purchase Mode and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Osteoarthritis Therapeutic (Value)
      • 7.2.1. Global Osteoarthritis Therapeutic by: Route of Administration (Value)
        • 7.2.1.1. Parenteral
        • 7.2.1.2. Topical
        • 7.2.1.3. Oral
      • 7.2.2. Global Osteoarthritis Therapeutic by: Distribution Channel (Value)
        • 7.2.2.1. Hospital Pharmacies
        • 7.2.2.2. Retail Pharmacies
        • 7.2.2.3. Online Pharmacies
      • 7.2.3. Global Osteoarthritis Therapeutic by: Anatomy (Value)
        • 7.2.3.1. Knee
        • 7.2.3.2. Hip
        • 7.2.3.3. Hand
        • 7.2.3.4. Small Joints (Foot & Ankle and Wrist )
      • 7.2.4. Global Osteoarthritis Therapeutic by: Purchase Mode (Value)
        • 7.2.4.1. Prescription Drug
        • 7.2.4.2. Over-the-counter Drug
      • 7.2.5. Global Osteoarthritis Therapeutic Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Osteoarthritis Therapeutic: by Route of Administration(USD Million)
  • Table 2. Osteoarthritis Therapeutic Parenteral , by Region USD Million (2015-2020)
  • Table 3. Osteoarthritis Therapeutic Topical , by Region USD Million (2015-2020)
  • Table 4. Osteoarthritis Therapeutic Oral , by Region USD Million (2015-2020)
  • Table 5. Osteoarthritis Therapeutic: by Distribution Channel(USD Million)
  • Table 6. Osteoarthritis Therapeutic Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 7. Osteoarthritis Therapeutic Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 8. Osteoarthritis Therapeutic Online Pharmacies , by Region USD Million (2015-2020)
  • Table 9. Osteoarthritis Therapeutic: by Anatomy(USD Million)
  • Table 10. Osteoarthritis Therapeutic Knee , by Region USD Million (2015-2020)
  • Table 11. Osteoarthritis Therapeutic Hip , by Region USD Million (2015-2020)
  • Table 12. Osteoarthritis Therapeutic Hand , by Region USD Million (2015-2020)
  • Table 13. Osteoarthritis Therapeutic Small Joints (Foot & Ankle and Wrist ) , by Region USD Million (2015-2020)
  • Table 14. Osteoarthritis Therapeutic: by Purchase Mode(USD Million)
  • Table 15. Osteoarthritis Therapeutic Prescription Drug , by Region USD Million (2015-2020)
  • Table 16. Osteoarthritis Therapeutic Over-the-counter Drug , by Region USD Million (2015-2020)
  • Table 17. South America Osteoarthritis Therapeutic, by Country USD Million (2015-2020)
  • Table 18. South America Osteoarthritis Therapeutic, by Drug USD Million (2015-2020)
  • Table 19. South America Osteoarthritis Therapeutic, by Route of Administration USD Million (2015-2020)
  • Table 20. South America Osteoarthritis Therapeutic, by Distribution Channel USD Million (2015-2020)
  • Table 21. South America Osteoarthritis Therapeutic, by Anatomy USD Million (2015-2020)
  • Table 22. South America Osteoarthritis Therapeutic, by Purchase Mode USD Million (2015-2020)
  • Table 23. Brazil Osteoarthritis Therapeutic, by Drug USD Million (2015-2020)
  • Table 24. Brazil Osteoarthritis Therapeutic, by Route of Administration USD Million (2015-2020)
  • Table 25. Brazil Osteoarthritis Therapeutic, by Distribution Channel USD Million (2015-2020)
  • Table 26. Brazil Osteoarthritis Therapeutic, by Anatomy USD Million (2015-2020)
  • Table 27. Brazil Osteoarthritis Therapeutic, by Purchase Mode USD Million (2015-2020)
  • Table 28. Argentina Osteoarthritis Therapeutic, by Drug USD Million (2015-2020)
  • Table 29. Argentina Osteoarthritis Therapeutic, by Route of Administration USD Million (2015-2020)
  • Table 30. Argentina Osteoarthritis Therapeutic, by Distribution Channel USD Million (2015-2020)
  • Table 31. Argentina Osteoarthritis Therapeutic, by Anatomy USD Million (2015-2020)
  • Table 32. Argentina Osteoarthritis Therapeutic, by Purchase Mode USD Million (2015-2020)
  • Table 33. Rest of South America Osteoarthritis Therapeutic, by Drug USD Million (2015-2020)
  • Table 34. Rest of South America Osteoarthritis Therapeutic, by Route of Administration USD Million (2015-2020)
  • Table 35. Rest of South America Osteoarthritis Therapeutic, by Distribution Channel USD Million (2015-2020)
  • Table 36. Rest of South America Osteoarthritis Therapeutic, by Anatomy USD Million (2015-2020)
  • Table 37. Rest of South America Osteoarthritis Therapeutic, by Purchase Mode USD Million (2015-2020)
  • Table 38. Asia Pacific Osteoarthritis Therapeutic, by Country USD Million (2015-2020)
  • Table 39. Asia Pacific Osteoarthritis Therapeutic, by Drug USD Million (2015-2020)
  • Table 40. Asia Pacific Osteoarthritis Therapeutic, by Route of Administration USD Million (2015-2020)
  • Table 41. Asia Pacific Osteoarthritis Therapeutic, by Distribution Channel USD Million (2015-2020)
  • Table 42. Asia Pacific Osteoarthritis Therapeutic, by Anatomy USD Million (2015-2020)
  • Table 43. Asia Pacific Osteoarthritis Therapeutic, by Purchase Mode USD Million (2015-2020)
  • Table 44. China Osteoarthritis Therapeutic, by Drug USD Million (2015-2020)
  • Table 45. China Osteoarthritis Therapeutic, by Route of Administration USD Million (2015-2020)
  • Table 46. China Osteoarthritis Therapeutic, by Distribution Channel USD Million (2015-2020)
  • Table 47. China Osteoarthritis Therapeutic, by Anatomy USD Million (2015-2020)
  • Table 48. China Osteoarthritis Therapeutic, by Purchase Mode USD Million (2015-2020)
  • Table 49. Japan Osteoarthritis Therapeutic, by Drug USD Million (2015-2020)
  • Table 50. Japan Osteoarthritis Therapeutic, by Route of Administration USD Million (2015-2020)
  • Table 51. Japan Osteoarthritis Therapeutic, by Distribution Channel USD Million (2015-2020)
  • Table 52. Japan Osteoarthritis Therapeutic, by Anatomy USD Million (2015-2020)
  • Table 53. Japan Osteoarthritis Therapeutic, by Purchase Mode USD Million (2015-2020)
  • Table 54. India Osteoarthritis Therapeutic, by Drug USD Million (2015-2020)
  • Table 55. India Osteoarthritis Therapeutic, by Route of Administration USD Million (2015-2020)
  • Table 56. India Osteoarthritis Therapeutic, by Distribution Channel USD Million (2015-2020)
  • Table 57. India Osteoarthritis Therapeutic, by Anatomy USD Million (2015-2020)
  • Table 58. India Osteoarthritis Therapeutic, by Purchase Mode USD Million (2015-2020)
  • Table 59. South Korea Osteoarthritis Therapeutic, by Drug USD Million (2015-2020)
  • Table 60. South Korea Osteoarthritis Therapeutic, by Route of Administration USD Million (2015-2020)
  • Table 61. South Korea Osteoarthritis Therapeutic, by Distribution Channel USD Million (2015-2020)
  • Table 62. South Korea Osteoarthritis Therapeutic, by Anatomy USD Million (2015-2020)
  • Table 63. South Korea Osteoarthritis Therapeutic, by Purchase Mode USD Million (2015-2020)
  • Table 64. Taiwan Osteoarthritis Therapeutic, by Drug USD Million (2015-2020)
  • Table 65. Taiwan Osteoarthritis Therapeutic, by Route of Administration USD Million (2015-2020)
  • Table 66. Taiwan Osteoarthritis Therapeutic, by Distribution Channel USD Million (2015-2020)
  • Table 67. Taiwan Osteoarthritis Therapeutic, by Anatomy USD Million (2015-2020)
  • Table 68. Taiwan Osteoarthritis Therapeutic, by Purchase Mode USD Million (2015-2020)
  • Table 69. Australia Osteoarthritis Therapeutic, by Drug USD Million (2015-2020)
  • Table 70. Australia Osteoarthritis Therapeutic, by Route of Administration USD Million (2015-2020)
  • Table 71. Australia Osteoarthritis Therapeutic, by Distribution Channel USD Million (2015-2020)
  • Table 72. Australia Osteoarthritis Therapeutic, by Anatomy USD Million (2015-2020)
  • Table 73. Australia Osteoarthritis Therapeutic, by Purchase Mode USD Million (2015-2020)
  • Table 74. Rest of Asia-Pacific Osteoarthritis Therapeutic, by Drug USD Million (2015-2020)
  • Table 75. Rest of Asia-Pacific Osteoarthritis Therapeutic, by Route of Administration USD Million (2015-2020)
  • Table 76. Rest of Asia-Pacific Osteoarthritis Therapeutic, by Distribution Channel USD Million (2015-2020)
  • Table 77. Rest of Asia-Pacific Osteoarthritis Therapeutic, by Anatomy USD Million (2015-2020)
  • Table 78. Rest of Asia-Pacific Osteoarthritis Therapeutic, by Purchase Mode USD Million (2015-2020)
  • Table 79. Europe Osteoarthritis Therapeutic, by Country USD Million (2015-2020)
  • Table 80. Europe Osteoarthritis Therapeutic, by Drug USD Million (2015-2020)
  • Table 81. Europe Osteoarthritis Therapeutic, by Route of Administration USD Million (2015-2020)
  • Table 82. Europe Osteoarthritis Therapeutic, by Distribution Channel USD Million (2015-2020)
  • Table 83. Europe Osteoarthritis Therapeutic, by Anatomy USD Million (2015-2020)
  • Table 84. Europe Osteoarthritis Therapeutic, by Purchase Mode USD Million (2015-2020)
  • Table 85. Germany Osteoarthritis Therapeutic, by Drug USD Million (2015-2020)
  • Table 86. Germany Osteoarthritis Therapeutic, by Route of Administration USD Million (2015-2020)
  • Table 87. Germany Osteoarthritis Therapeutic, by Distribution Channel USD Million (2015-2020)
  • Table 88. Germany Osteoarthritis Therapeutic, by Anatomy USD Million (2015-2020)
  • Table 89. Germany Osteoarthritis Therapeutic, by Purchase Mode USD Million (2015-2020)
  • Table 90. France Osteoarthritis Therapeutic, by Drug USD Million (2015-2020)
  • Table 91. France Osteoarthritis Therapeutic, by Route of Administration USD Million (2015-2020)
  • Table 92. France Osteoarthritis Therapeutic, by Distribution Channel USD Million (2015-2020)
  • Table 93. France Osteoarthritis Therapeutic, by Anatomy USD Million (2015-2020)
  • Table 94. France Osteoarthritis Therapeutic, by Purchase Mode USD Million (2015-2020)
  • Table 95. Italy Osteoarthritis Therapeutic, by Drug USD Million (2015-2020)
  • Table 96. Italy Osteoarthritis Therapeutic, by Route of Administration USD Million (2015-2020)
  • Table 97. Italy Osteoarthritis Therapeutic, by Distribution Channel USD Million (2015-2020)
  • Table 98. Italy Osteoarthritis Therapeutic, by Anatomy USD Million (2015-2020)
  • Table 99. Italy Osteoarthritis Therapeutic, by Purchase Mode USD Million (2015-2020)
  • Table 100. United Kingdom Osteoarthritis Therapeutic, by Drug USD Million (2015-2020)
  • Table 101. United Kingdom Osteoarthritis Therapeutic, by Route of Administration USD Million (2015-2020)
  • Table 102. United Kingdom Osteoarthritis Therapeutic, by Distribution Channel USD Million (2015-2020)
  • Table 103. United Kingdom Osteoarthritis Therapeutic, by Anatomy USD Million (2015-2020)
  • Table 104. United Kingdom Osteoarthritis Therapeutic, by Purchase Mode USD Million (2015-2020)
  • Table 105. Netherlands Osteoarthritis Therapeutic, by Drug USD Million (2015-2020)
  • Table 106. Netherlands Osteoarthritis Therapeutic, by Route of Administration USD Million (2015-2020)
  • Table 107. Netherlands Osteoarthritis Therapeutic, by Distribution Channel USD Million (2015-2020)
  • Table 108. Netherlands Osteoarthritis Therapeutic, by Anatomy USD Million (2015-2020)
  • Table 109. Netherlands Osteoarthritis Therapeutic, by Purchase Mode USD Million (2015-2020)
  • Table 110. Rest of Europe Osteoarthritis Therapeutic, by Drug USD Million (2015-2020)
  • Table 111. Rest of Europe Osteoarthritis Therapeutic, by Route of Administration USD Million (2015-2020)
  • Table 112. Rest of Europe Osteoarthritis Therapeutic, by Distribution Channel USD Million (2015-2020)
  • Table 113. Rest of Europe Osteoarthritis Therapeutic, by Anatomy USD Million (2015-2020)
  • Table 114. Rest of Europe Osteoarthritis Therapeutic, by Purchase Mode USD Million (2015-2020)
  • Table 115. MEA Osteoarthritis Therapeutic, by Country USD Million (2015-2020)
  • Table 116. MEA Osteoarthritis Therapeutic, by Drug USD Million (2015-2020)
  • Table 117. MEA Osteoarthritis Therapeutic, by Route of Administration USD Million (2015-2020)
  • Table 118. MEA Osteoarthritis Therapeutic, by Distribution Channel USD Million (2015-2020)
  • Table 119. MEA Osteoarthritis Therapeutic, by Anatomy USD Million (2015-2020)
  • Table 120. MEA Osteoarthritis Therapeutic, by Purchase Mode USD Million (2015-2020)
  • Table 121. Middle East Osteoarthritis Therapeutic, by Drug USD Million (2015-2020)
  • Table 122. Middle East Osteoarthritis Therapeutic, by Route of Administration USD Million (2015-2020)
  • Table 123. Middle East Osteoarthritis Therapeutic, by Distribution Channel USD Million (2015-2020)
  • Table 124. Middle East Osteoarthritis Therapeutic, by Anatomy USD Million (2015-2020)
  • Table 125. Middle East Osteoarthritis Therapeutic, by Purchase Mode USD Million (2015-2020)
  • Table 126. Africa Osteoarthritis Therapeutic, by Drug USD Million (2015-2020)
  • Table 127. Africa Osteoarthritis Therapeutic, by Route of Administration USD Million (2015-2020)
  • Table 128. Africa Osteoarthritis Therapeutic, by Distribution Channel USD Million (2015-2020)
  • Table 129. Africa Osteoarthritis Therapeutic, by Anatomy USD Million (2015-2020)
  • Table 130. Africa Osteoarthritis Therapeutic, by Purchase Mode USD Million (2015-2020)
  • Table 131. North America Osteoarthritis Therapeutic, by Country USD Million (2015-2020)
  • Table 132. North America Osteoarthritis Therapeutic, by Drug USD Million (2015-2020)
  • Table 133. North America Osteoarthritis Therapeutic, by Route of Administration USD Million (2015-2020)
  • Table 134. North America Osteoarthritis Therapeutic, by Distribution Channel USD Million (2015-2020)
  • Table 135. North America Osteoarthritis Therapeutic, by Anatomy USD Million (2015-2020)
  • Table 136. North America Osteoarthritis Therapeutic, by Purchase Mode USD Million (2015-2020)
  • Table 137. United States Osteoarthritis Therapeutic, by Drug USD Million (2015-2020)
  • Table 138. United States Osteoarthritis Therapeutic, by Route of Administration USD Million (2015-2020)
  • Table 139. United States Osteoarthritis Therapeutic, by Distribution Channel USD Million (2015-2020)
  • Table 140. United States Osteoarthritis Therapeutic, by Anatomy USD Million (2015-2020)
  • Table 141. United States Osteoarthritis Therapeutic, by Purchase Mode USD Million (2015-2020)
  • Table 142. Canada Osteoarthritis Therapeutic, by Drug USD Million (2015-2020)
  • Table 143. Canada Osteoarthritis Therapeutic, by Route of Administration USD Million (2015-2020)
  • Table 144. Canada Osteoarthritis Therapeutic, by Distribution Channel USD Million (2015-2020)
  • Table 145. Canada Osteoarthritis Therapeutic, by Anatomy USD Million (2015-2020)
  • Table 146. Canada Osteoarthritis Therapeutic, by Purchase Mode USD Million (2015-2020)
  • Table 147. Mexico Osteoarthritis Therapeutic, by Drug USD Million (2015-2020)
  • Table 148. Mexico Osteoarthritis Therapeutic, by Route of Administration USD Million (2015-2020)
  • Table 149. Mexico Osteoarthritis Therapeutic, by Distribution Channel USD Million (2015-2020)
  • Table 150. Mexico Osteoarthritis Therapeutic, by Anatomy USD Million (2015-2020)
  • Table 151. Mexico Osteoarthritis Therapeutic, by Purchase Mode USD Million (2015-2020)
  • Table 152. Company Basic Information, Sales Area and Its Competitors
  • Table 153. Company Basic Information, Sales Area and Its Competitors
  • Table 154. Company Basic Information, Sales Area and Its Competitors
  • Table 155. Company Basic Information, Sales Area and Its Competitors
  • Table 156. Company Basic Information, Sales Area and Its Competitors
  • Table 157. Company Basic Information, Sales Area and Its Competitors
  • Table 158. Company Basic Information, Sales Area and Its Competitors
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Osteoarthritis Therapeutic: by Route of Administration(USD Million)
  • Table 163. Osteoarthritis Therapeutic Parenteral , by Region USD Million (2021-2026)
  • Table 164. Osteoarthritis Therapeutic Topical , by Region USD Million (2021-2026)
  • Table 165. Osteoarthritis Therapeutic Oral , by Region USD Million (2021-2026)
  • Table 166. Osteoarthritis Therapeutic: by Distribution Channel(USD Million)
  • Table 167. Osteoarthritis Therapeutic Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 168. Osteoarthritis Therapeutic Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 169. Osteoarthritis Therapeutic Online Pharmacies , by Region USD Million (2021-2026)
  • Table 170. Osteoarthritis Therapeutic: by Anatomy(USD Million)
  • Table 171. Osteoarthritis Therapeutic Knee , by Region USD Million (2021-2026)
  • Table 172. Osteoarthritis Therapeutic Hip , by Region USD Million (2021-2026)
  • Table 173. Osteoarthritis Therapeutic Hand , by Region USD Million (2021-2026)
  • Table 174. Osteoarthritis Therapeutic Small Joints (Foot & Ankle and Wrist ) , by Region USD Million (2021-2026)
  • Table 175. Osteoarthritis Therapeutic: by Purchase Mode(USD Million)
  • Table 176. Osteoarthritis Therapeutic Prescription Drug , by Region USD Million (2021-2026)
  • Table 177. Osteoarthritis Therapeutic Over-the-counter Drug , by Region USD Million (2021-2026)
  • Table 178. South America Osteoarthritis Therapeutic, by Country USD Million (2021-2026)
  • Table 179. South America Osteoarthritis Therapeutic, by Drug USD Million (2021-2026)
  • Table 180. South America Osteoarthritis Therapeutic, by Route of Administration USD Million (2021-2026)
  • Table 181. South America Osteoarthritis Therapeutic, by Distribution Channel USD Million (2021-2026)
  • Table 182. South America Osteoarthritis Therapeutic, by Anatomy USD Million (2021-2026)
  • Table 183. South America Osteoarthritis Therapeutic, by Purchase Mode USD Million (2021-2026)
  • Table 184. Brazil Osteoarthritis Therapeutic, by Drug USD Million (2021-2026)
  • Table 185. Brazil Osteoarthritis Therapeutic, by Route of Administration USD Million (2021-2026)
  • Table 186. Brazil Osteoarthritis Therapeutic, by Distribution Channel USD Million (2021-2026)
  • Table 187. Brazil Osteoarthritis Therapeutic, by Anatomy USD Million (2021-2026)
  • Table 188. Brazil Osteoarthritis Therapeutic, by Purchase Mode USD Million (2021-2026)
  • Table 189. Argentina Osteoarthritis Therapeutic, by Drug USD Million (2021-2026)
  • Table 190. Argentina Osteoarthritis Therapeutic, by Route of Administration USD Million (2021-2026)
  • Table 191. Argentina Osteoarthritis Therapeutic, by Distribution Channel USD Million (2021-2026)
  • Table 192. Argentina Osteoarthritis Therapeutic, by Anatomy USD Million (2021-2026)
  • Table 193. Argentina Osteoarthritis Therapeutic, by Purchase Mode USD Million (2021-2026)
  • Table 194. Rest of South America Osteoarthritis Therapeutic, by Drug USD Million (2021-2026)
  • Table 195. Rest of South America Osteoarthritis Therapeutic, by Route of Administration USD Million (2021-2026)
  • Table 196. Rest of South America Osteoarthritis Therapeutic, by Distribution Channel USD Million (2021-2026)
  • Table 197. Rest of South America Osteoarthritis Therapeutic, by Anatomy USD Million (2021-2026)
  • Table 198. Rest of South America Osteoarthritis Therapeutic, by Purchase Mode USD Million (2021-2026)
  • Table 199. Asia Pacific Osteoarthritis Therapeutic, by Country USD Million (2021-2026)
  • Table 200. Asia Pacific Osteoarthritis Therapeutic, by Drug USD Million (2021-2026)
  • Table 201. Asia Pacific Osteoarthritis Therapeutic, by Route of Administration USD Million (2021-2026)
  • Table 202. Asia Pacific Osteoarthritis Therapeutic, by Distribution Channel USD Million (2021-2026)
  • Table 203. Asia Pacific Osteoarthritis Therapeutic, by Anatomy USD Million (2021-2026)
  • Table 204. Asia Pacific Osteoarthritis Therapeutic, by Purchase Mode USD Million (2021-2026)
  • Table 205. China Osteoarthritis Therapeutic, by Drug USD Million (2021-2026)
  • Table 206. China Osteoarthritis Therapeutic, by Route of Administration USD Million (2021-2026)
  • Table 207. China Osteoarthritis Therapeutic, by Distribution Channel USD Million (2021-2026)
  • Table 208. China Osteoarthritis Therapeutic, by Anatomy USD Million (2021-2026)
  • Table 209. China Osteoarthritis Therapeutic, by Purchase Mode USD Million (2021-2026)
  • Table 210. Japan Osteoarthritis Therapeutic, by Drug USD Million (2021-2026)
  • Table 211. Japan Osteoarthritis Therapeutic, by Route of Administration USD Million (2021-2026)
  • Table 212. Japan Osteoarthritis Therapeutic, by Distribution Channel USD Million (2021-2026)
  • Table 213. Japan Osteoarthritis Therapeutic, by Anatomy USD Million (2021-2026)
  • Table 214. Japan Osteoarthritis Therapeutic, by Purchase Mode USD Million (2021-2026)
  • Table 215. India Osteoarthritis Therapeutic, by Drug USD Million (2021-2026)
  • Table 216. India Osteoarthritis Therapeutic, by Route of Administration USD Million (2021-2026)
  • Table 217. India Osteoarthritis Therapeutic, by Distribution Channel USD Million (2021-2026)
  • Table 218. India Osteoarthritis Therapeutic, by Anatomy USD Million (2021-2026)
  • Table 219. India Osteoarthritis Therapeutic, by Purchase Mode USD Million (2021-2026)
  • Table 220. South Korea Osteoarthritis Therapeutic, by Drug USD Million (2021-2026)
  • Table 221. South Korea Osteoarthritis Therapeutic, by Route of Administration USD Million (2021-2026)
  • Table 222. South Korea Osteoarthritis Therapeutic, by Distribution Channel USD Million (2021-2026)
  • Table 223. South Korea Osteoarthritis Therapeutic, by Anatomy USD Million (2021-2026)
  • Table 224. South Korea Osteoarthritis Therapeutic, by Purchase Mode USD Million (2021-2026)
  • Table 225. Taiwan Osteoarthritis Therapeutic, by Drug USD Million (2021-2026)
  • Table 226. Taiwan Osteoarthritis Therapeutic, by Route of Administration USD Million (2021-2026)
  • Table 227. Taiwan Osteoarthritis Therapeutic, by Distribution Channel USD Million (2021-2026)
  • Table 228. Taiwan Osteoarthritis Therapeutic, by Anatomy USD Million (2021-2026)
  • Table 229. Taiwan Osteoarthritis Therapeutic, by Purchase Mode USD Million (2021-2026)
  • Table 230. Australia Osteoarthritis Therapeutic, by Drug USD Million (2021-2026)
  • Table 231. Australia Osteoarthritis Therapeutic, by Route of Administration USD Million (2021-2026)
  • Table 232. Australia Osteoarthritis Therapeutic, by Distribution Channel USD Million (2021-2026)
  • Table 233. Australia Osteoarthritis Therapeutic, by Anatomy USD Million (2021-2026)
  • Table 234. Australia Osteoarthritis Therapeutic, by Purchase Mode USD Million (2021-2026)
  • Table 235. Rest of Asia-Pacific Osteoarthritis Therapeutic, by Drug USD Million (2021-2026)
  • Table 236. Rest of Asia-Pacific Osteoarthritis Therapeutic, by Route of Administration USD Million (2021-2026)
  • Table 237. Rest of Asia-Pacific Osteoarthritis Therapeutic, by Distribution Channel USD Million (2021-2026)
  • Table 238. Rest of Asia-Pacific Osteoarthritis Therapeutic, by Anatomy USD Million (2021-2026)
  • Table 239. Rest of Asia-Pacific Osteoarthritis Therapeutic, by Purchase Mode USD Million (2021-2026)
  • Table 240. Europe Osteoarthritis Therapeutic, by Country USD Million (2021-2026)
  • Table 241. Europe Osteoarthritis Therapeutic, by Drug USD Million (2021-2026)
  • Table 242. Europe Osteoarthritis Therapeutic, by Route of Administration USD Million (2021-2026)
  • Table 243. Europe Osteoarthritis Therapeutic, by Distribution Channel USD Million (2021-2026)
  • Table 244. Europe Osteoarthritis Therapeutic, by Anatomy USD Million (2021-2026)
  • Table 245. Europe Osteoarthritis Therapeutic, by Purchase Mode USD Million (2021-2026)
  • Table 246. Germany Osteoarthritis Therapeutic, by Drug USD Million (2021-2026)
  • Table 247. Germany Osteoarthritis Therapeutic, by Route of Administration USD Million (2021-2026)
  • Table 248. Germany Osteoarthritis Therapeutic, by Distribution Channel USD Million (2021-2026)
  • Table 249. Germany Osteoarthritis Therapeutic, by Anatomy USD Million (2021-2026)
  • Table 250. Germany Osteoarthritis Therapeutic, by Purchase Mode USD Million (2021-2026)
  • Table 251. France Osteoarthritis Therapeutic, by Drug USD Million (2021-2026)
  • Table 252. France Osteoarthritis Therapeutic, by Route of Administration USD Million (2021-2026)
  • Table 253. France Osteoarthritis Therapeutic, by Distribution Channel USD Million (2021-2026)
  • Table 254. France Osteoarthritis Therapeutic, by Anatomy USD Million (2021-2026)
  • Table 255. France Osteoarthritis Therapeutic, by Purchase Mode USD Million (2021-2026)
  • Table 256. Italy Osteoarthritis Therapeutic, by Drug USD Million (2021-2026)
  • Table 257. Italy Osteoarthritis Therapeutic, by Route of Administration USD Million (2021-2026)
  • Table 258. Italy Osteoarthritis Therapeutic, by Distribution Channel USD Million (2021-2026)
  • Table 259. Italy Osteoarthritis Therapeutic, by Anatomy USD Million (2021-2026)
  • Table 260. Italy Osteoarthritis Therapeutic, by Purchase Mode USD Million (2021-2026)
  • Table 261. United Kingdom Osteoarthritis Therapeutic, by Drug USD Million (2021-2026)
  • Table 262. United Kingdom Osteoarthritis Therapeutic, by Route of Administration USD Million (2021-2026)
  • Table 263. United Kingdom Osteoarthritis Therapeutic, by Distribution Channel USD Million (2021-2026)
  • Table 264. United Kingdom Osteoarthritis Therapeutic, by Anatomy USD Million (2021-2026)
  • Table 265. United Kingdom Osteoarthritis Therapeutic, by Purchase Mode USD Million (2021-2026)
  • Table 266. Netherlands Osteoarthritis Therapeutic, by Drug USD Million (2021-2026)
  • Table 267. Netherlands Osteoarthritis Therapeutic, by Route of Administration USD Million (2021-2026)
  • Table 268. Netherlands Osteoarthritis Therapeutic, by Distribution Channel USD Million (2021-2026)
  • Table 269. Netherlands Osteoarthritis Therapeutic, by Anatomy USD Million (2021-2026)
  • Table 270. Netherlands Osteoarthritis Therapeutic, by Purchase Mode USD Million (2021-2026)
  • Table 271. Rest of Europe Osteoarthritis Therapeutic, by Drug USD Million (2021-2026)
  • Table 272. Rest of Europe Osteoarthritis Therapeutic, by Route of Administration USD Million (2021-2026)
  • Table 273. Rest of Europe Osteoarthritis Therapeutic, by Distribution Channel USD Million (2021-2026)
  • Table 274. Rest of Europe Osteoarthritis Therapeutic, by Anatomy USD Million (2021-2026)
  • Table 275. Rest of Europe Osteoarthritis Therapeutic, by Purchase Mode USD Million (2021-2026)
  • Table 276. MEA Osteoarthritis Therapeutic, by Country USD Million (2021-2026)
  • Table 277. MEA Osteoarthritis Therapeutic, by Drug USD Million (2021-2026)
  • Table 278. MEA Osteoarthritis Therapeutic, by Route of Administration USD Million (2021-2026)
  • Table 279. MEA Osteoarthritis Therapeutic, by Distribution Channel USD Million (2021-2026)
  • Table 280. MEA Osteoarthritis Therapeutic, by Anatomy USD Million (2021-2026)
  • Table 281. MEA Osteoarthritis Therapeutic, by Purchase Mode USD Million (2021-2026)
  • Table 282. Middle East Osteoarthritis Therapeutic, by Drug USD Million (2021-2026)
  • Table 283. Middle East Osteoarthritis Therapeutic, by Route of Administration USD Million (2021-2026)
  • Table 284. Middle East Osteoarthritis Therapeutic, by Distribution Channel USD Million (2021-2026)
  • Table 285. Middle East Osteoarthritis Therapeutic, by Anatomy USD Million (2021-2026)
  • Table 286. Middle East Osteoarthritis Therapeutic, by Purchase Mode USD Million (2021-2026)
  • Table 287. Africa Osteoarthritis Therapeutic, by Drug USD Million (2021-2026)
  • Table 288. Africa Osteoarthritis Therapeutic, by Route of Administration USD Million (2021-2026)
  • Table 289. Africa Osteoarthritis Therapeutic, by Distribution Channel USD Million (2021-2026)
  • Table 290. Africa Osteoarthritis Therapeutic, by Anatomy USD Million (2021-2026)
  • Table 291. Africa Osteoarthritis Therapeutic, by Purchase Mode USD Million (2021-2026)
  • Table 292. North America Osteoarthritis Therapeutic, by Country USD Million (2021-2026)
  • Table 293. North America Osteoarthritis Therapeutic, by Drug USD Million (2021-2026)
  • Table 294. North America Osteoarthritis Therapeutic, by Route of Administration USD Million (2021-2026)
  • Table 295. North America Osteoarthritis Therapeutic, by Distribution Channel USD Million (2021-2026)
  • Table 296. North America Osteoarthritis Therapeutic, by Anatomy USD Million (2021-2026)
  • Table 297. North America Osteoarthritis Therapeutic, by Purchase Mode USD Million (2021-2026)
  • Table 298. United States Osteoarthritis Therapeutic, by Drug USD Million (2021-2026)
  • Table 299. United States Osteoarthritis Therapeutic, by Route of Administration USD Million (2021-2026)
  • Table 300. United States Osteoarthritis Therapeutic, by Distribution Channel USD Million (2021-2026)
  • Table 301. United States Osteoarthritis Therapeutic, by Anatomy USD Million (2021-2026)
  • Table 302. United States Osteoarthritis Therapeutic, by Purchase Mode USD Million (2021-2026)
  • Table 303. Canada Osteoarthritis Therapeutic, by Drug USD Million (2021-2026)
  • Table 304. Canada Osteoarthritis Therapeutic, by Route of Administration USD Million (2021-2026)
  • Table 305. Canada Osteoarthritis Therapeutic, by Distribution Channel USD Million (2021-2026)
  • Table 306. Canada Osteoarthritis Therapeutic, by Anatomy USD Million (2021-2026)
  • Table 307. Canada Osteoarthritis Therapeutic, by Purchase Mode USD Million (2021-2026)
  • Table 308. Mexico Osteoarthritis Therapeutic, by Drug USD Million (2021-2026)
  • Table 309. Mexico Osteoarthritis Therapeutic, by Route of Administration USD Million (2021-2026)
  • Table 310. Mexico Osteoarthritis Therapeutic, by Distribution Channel USD Million (2021-2026)
  • Table 311. Mexico Osteoarthritis Therapeutic, by Anatomy USD Million (2021-2026)
  • Table 312. Mexico Osteoarthritis Therapeutic, by Purchase Mode USD Million (2021-2026)
  • Table 313. Research Programs/Design for This Report
  • Table 314. Key Data Information from Secondary Sources
  • Table 315. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Osteoarthritis Therapeutic: by Route of Administration USD Million (2015-2020)
  • Figure 5. Global Osteoarthritis Therapeutic: by Distribution Channel USD Million (2015-2020)
  • Figure 6. Global Osteoarthritis Therapeutic: by Anatomy USD Million (2015-2020)
  • Figure 7. Global Osteoarthritis Therapeutic: by Purchase Mode USD Million (2015-2020)
  • Figure 8. South America Osteoarthritis Therapeutic Share (%), by Country
  • Figure 9. Asia Pacific Osteoarthritis Therapeutic Share (%), by Country
  • Figure 10. Europe Osteoarthritis Therapeutic Share (%), by Country
  • Figure 11. MEA Osteoarthritis Therapeutic Share (%), by Country
  • Figure 12. North America Osteoarthritis Therapeutic Share (%), by Country
  • Figure 13. Global Osteoarthritis Therapeutic share by Players 2020 (%)
  • Figure 14. Global Osteoarthritis Therapeutic share by Players (Top 3) 2020(%)
  • Figure 15. Global Osteoarthritis Therapeutic share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 18. Sanofi (France) Revenue: by Geography 2020
  • Figure 19. Horizon Therapeutics (Ireland) Revenue, Net Income and Gross profit
  • Figure 20. Horizon Therapeutics (Ireland) Revenue: by Geography 2020
  • Figure 21. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 22. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 23. GlaxoSmithKline Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 24. GlaxoSmithKline Plc (United Kingdom) Revenue: by Geography 2020
  • Figure 25. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 26. Bayer AG (Germany) Revenue: by Geography 2020
  • Figure 27. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 28. Abbott (United States) Revenue: by Geography 2020
  • Figure 29. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 30. Pfizer (United States) Revenue: by Geography 2020
  • Figure 31. Eli Lilly (United States) Revenue, Net Income and Gross profit
  • Figure 32. Eli Lilly (United States) Revenue: by Geography 2020
  • Figure 33. Anika Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 34. Anika Therapeutics (United States) Revenue: by Geography 2020
  • Figure 35. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 36. Novartis (Switzerland) Revenue: by Geography 2020
  • Figure 37. Global Osteoarthritis Therapeutic: by Route of Administration USD Million (2021-2026)
  • Figure 38. Global Osteoarthritis Therapeutic: by Distribution Channel USD Million (2021-2026)
  • Figure 39. Global Osteoarthritis Therapeutic: by Anatomy USD Million (2021-2026)
  • Figure 40. Global Osteoarthritis Therapeutic: by Purchase Mode USD Million (2021-2026)
  • Figure 41. South America Osteoarthritis Therapeutic Share (%), by Country
  • Figure 42. Asia Pacific Osteoarthritis Therapeutic Share (%), by Country
  • Figure 43. Europe Osteoarthritis Therapeutic Share (%), by Country
  • Figure 44. MEA Osteoarthritis Therapeutic Share (%), by Country
  • Figure 45. North America Osteoarthritis Therapeutic Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Sanofi (France)
  • Horizon Therapeutics (Ireland)
  • Johnson & Johnson (United States)
  • GlaxoSmithKline Plc (United Kingdom)
  • Bayer AG (Germany)
  • Abbott (United States)
  • Pfizer (United States)
  • Eli Lilly (United States)
  • Anika Therapeutics (United States)
  • Novartis (Switzerland)
Additional players considered in the study are as follows:
Bioventus (United States) , Zimmer Biomet Holdings, Inc.(United States) , Flexion Therapeutics (United States) , Fidia Farmaceutici s.p.a. (Italy)
Select User Access Type

Key Highlights of Report


Feb 2022 216 Pages 68 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Osteoarthritis Therapeutic Market Quantitative research analysis
Global Osteoarthritis Therapeutic Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Sanofi (France), Horizon Therapeutics (Ireland), Johnson & Johnson (United States), GlaxoSmithKline Plc (United Kingdom), Bayer AG (Germany), Abbott (United States), Pfizer (United States), Eli Lilly (United States), Anika Therapeutics (United States) and Novartis (Switzerland) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
Analysts at AMA estimates Osteoarthritis Therapeutic Market to reach USD Million by 2026.

Know More About Global Osteoarthritis Therapeutic Market Report?

Have a Query? Click Here

Other Related Reports

Mechanical Thrombectomy Devices  Comprehensive Study by Type (Stroke, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Others), Application (Cardiovascular, Peripheral Vascular, Neurovascular), E...
$ 3650
Pressotherapy Systems Comprehensive Study by Application (Veno-lymphatic circulation, Cellulite at different stages, Adiposity edema, Reduction of swelling, Tired legs, Others), End-User (Hospitals, ...
$ 3500
Air Oxygen Blender Comprehensive Study by Application (Intensive Care Unit (ICU), Neonatal Intensive Care Unit (NICU), Recovery and High Dependency Units, Ambulances, Others), Configuration (Low Flow...
$ 3650
Biopsy Needle Comprehensive Study by Application (Tumor, Infection, Inflammation, Others), Working (Fully Automatic, Semi-Automatic), Utility (Disposable Needle, Non Disposable Needle), End User (Hos...
$ 3350
Cardiac Mapping Comprehensive Study by Type (Contact Cardiac Mapping Systems (Electroanatomical Mapping, Basket catheter Mapping, Traditional Endocardial, Catheter Mapping), Non-contact Cardiac Mappi...
$ 3750
Intra aortic Balloon Pump Comprehensive Study by Type (Fiber Optic, Ordinary), Application (Cardiogenic shock, Arrhythmia, Unstable angina, Heart failure), Balloon Sizes (34 cc, 50 cc, 40 cc), End Us...
$ 3450